RxDoctor Payments Data

Camilo Gomez, MD

Interventional Cardiology · Miami, FLNPI 1386900637

Payments from drug & device makers

$30,950in general payments, 2019–2025

Across 238 payments — averaging $130.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$22K
  • Abbott$2K
  • Edwards Lifesciences$1K
  • Inari Medical, Inc.$862
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$657
  • Penumbra, Inc.$476
  • plus $4K from 35 others

What the payments were for

  • Grants$18,00058%
  • Travel & lodging$1,7696%
  • Food & beverage$11,09336%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,950 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$69,451
Medicare patients
273
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$28,037
EntrestoSacubitril/Valsartan33$25,159
FarxigaDapagliflozin Propanediol19$12,416
BrilintaTicagrelor14$7,301
Rosuvastatin Calcium36$341
Nifedipine ErNifedipine21$217
Furosemide45$150
Atorvastatin Calcium31$147
Amlodipine Besylate14$134
Ezetimibe18$129
Spironolactone25$123
Carvedilol22$122
Losartan Potassium35$107
ClopidogrelClopidogrel Bisulfate25$99
Metoprolol Succinate26$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$28,03735 claims
NovartisEntresto$207$25,15933 claims
AstraZenecaFarxiga, Brilinta$310$19,71733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →